Newcastle University

Roles and Responsibilities

Professor of Childhood Cancer Cytogenetics
Director, Leukaemia Research Cytogenetics Group

Qualifications

Clinical Scientist, registered with Health Professions Council
Registration No. CS.08207
2001: Fellowship Royal College of Pathologists
1978: PhD Cell Biology Faculty of Medicine, University of Manchester
1975: BSc Genetics & Cell Biology, University of Manchester

Previous Positions

2001-2008 Reader/Professor of Cancer Cytogenetics & Director, Leukaemia Research Cytogenetics Group, University of Southampton
1997-2001 Director, Leukaemia Research Cytogenetics Group, University of London; Head, Cytogenetics, Dept of Haematology, Royal Free And University College Medical School, London

Memberships

Member, International Standing Committee on Human Cytogenetic Nomenclature
Member, American Society of Hematology

Esteem Indicators

Section Editor, "Leukemia"
Assessor in Genetics (Cytogenetics and Molecular Genetics) Department of Health, Panel of Assessors
Chairman, United Kingdom Cancer Cytogenetics Group
Chairman, Joint Steering Committee for the Association of Clinical Cytogeneticists Leukaemia Working Party and the United Kingdom Cancer Cytogenetics Group
Moderator and abstract reviewer for American Society of Hematology Annual Meeting, 2007

Undergraduate Teaching

Biomedical Sciences Plus

Postgraduate Teaching

PhD Examiner:
University of Lund, Sweden 2003 and 2006 (two students)
University of Sheffield (five students)
University of Cardiff (two students)
University of Newcastle (one student)

MD examiner:
University of Sheffield (one student)
University of London (one student)
University of Southampton (one student)

• Ensor HM, Schwab C, Russell LJ, Richards SM, Morrison H, Masic D, Jones L, Kinsey SE, Vora AJ, Mitchell CD, Harrison CJ, Moorman AV. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 2011, 117(7), 2129-2136.
• Coenen EA, Raimondi SC, Harbott J, Martin Z, Balgobind BV, Alonzo TA, Auvrignon A, Beverloo B, Chang MR, Creutzig U, Dworzak M, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJ, Leszl A, Litvinko N, lo Nigro L, Morimoto A, Perot C, Reinhardt D, Rubnitz J, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Pieters R, Zwaan CM, Eibrink MV. Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL Rearranged AML Results from an International Retrospective Study. In: Blood: 42nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Buitenkamp TD, Pieters R, Zimmermann M, de Haas V, Richards SM, Vora AJ, Mitchell CD, Schwab C, Harrison CJ, Moorman AV, van den Heuvel-Eibrink MM, Zwaan CM. BTG1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia. Leukemia 2013, 27(1), 251-252.
• Al-Shehhi H, Konn ZJ, Schwab CJ, Erhorn A, Barber KE, Wright SL, Gabriel AS, Harrison CJ, Moorman AV. Abnormalities of the der(12)t(12;21) in ETV6-RUNX1 acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2013, 52(2), 202-213.
• Safavi S, Forestier E, Golovleva I, Barbany G, Nord KH, Moorman AV, Harrison CJ, Johansson B, Paulsson K. Loss of chromosomes is the primary event in near-haploid and low-hypodiploid acute lymphoblastic leukemia. Leukemia 2013, 27(1), 248-250.
• Moorman AV, Robinson H, Schwab C, Richards SM, Hancock J, Mitchell CD, Goulden N, Vora A, Harrison CJ. Risk directed treatment intensification significantly reduces the risk of relapse among children with acute lymphoblastic leukaemia and intrachromosomal amplification of chromosome 21. Journal of Clinical Oncology 2013. Submitted.
• Marks DI, Moorman AV, Chilton L, Paietta E, Enshaie A, DeWald G, Harrison C, Fielding AK, Foroni L, Goldstone AH, Litzow MR, Luger SM, McMillan AK, Racevskis J, Rowe JM, Tallman MS, Wiernik P, Lazarus HM. The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated on UKALLXII/ECOG2993. Haematologica 2013, (epub ahead of print).
• Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S. Burkitt's lymphoma. Lancet 2012, 379(9822), 1234-1244.
• Reedijk A, Kaspers G, Fiocco M, Pession A, Reinhardt D, Zimmermann M, Dworzak M, Alonzo TA, Johnston D, Zapotocky M, De Moerloose B, Finita F, Lee V, Taga T, Tawa A, Auvrignon A, Zeller B, Salgado C, Balwierz W, Popa A, Rubnitz J, Beverloo HBB, Harrison CJ, Gibson B. Clinical Impact of Additional Cytogenetic Aberrations and Treatment in Pediatric t(8;21)-Positive AML: Results from an International Retrospective I-BFM-SG Study. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Schwab C, Chilton L, Enshaie A, Morrison H, Jones L, Al-Shehhi HA, Erhorn A, Russell LJ, Vora AJ, Mitchell CD, Richards SM, Goulden N, Kinsey S, Moorman AV, Harrison CJ. Clinical Relevance of Genes Commonly Deleted in Childhood B-Cell Precursor ALL (BCP-ALL). In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Moorman AV, Enshaie A, Chilton L, Schwab C, Tembo T, Richards S, Kinsey S, Vora AJ, Mitchell C, Harrison CJ. Delineation of Risk Factors in Paediatric Acute Lymphoblastic Leukaemia with Favourable Cytogenetics. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Eyre T, Schwab CJ, Kinstrie R, McGuire AK, Strefford J, Peniket A, Mead A, Littlewood T, Holyoake TL, Copland M, Moorman AV, Harrison CJ, Vyas P. Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood 2012, 120(22), 4441-4443.
• Schwab C, Chilton L, Morrison H, Jones L, Al-Shehhi HA, Erhorn A, Russell LJ, Moorman AV, Harrison CJ. Genes Commonly Deleted in Childhood B-Cell Precursor ALL (BCP-ALL) Are Associated with Major Cytogenetic Subgroups. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Harrison CJ. Genomic Analysis Drives Tailored Therapy in Poor Risk Childhood Leukemia. Cancer Cell 2012, 22(2), 139-140.
• Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, Masic D, Patel B, Rowe JM, Tallman M, Goldstone AH, Fielding AK, Harrison CJ. IGH@ Translocations, CRLF2 Deregulation and Microdeletions in Adolescents and Adults with Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 2012, 30(25), 3100-3108.
• Russell LJ, Jones L, Erhorn A, Ensahei A, Masic D, Bentley H, Laczko KS, Harrison CJ. Immunoglobulin Heavy Chain Locus (IGH@) Translocations in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Incidence and Risk Stratification. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Harrison CJ, Moorman AV, Schwab C, Heerema NA, Carroll AJ, Haas OA. Intrachromosomal Amplification of Chromosome 21(iAMP21): Cytogenetic Characterisation and Outcome in Childhood B-Cell Precursor Acute Lymphoblastic Leukaemia (BCP-ALL). A Study On Behalf of the Ponte Di Legno International Childhood ALL Workshop. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Van Der Veer A, Waanders E, Pieters R, Willemse ME, Reijmersdaal S, Russell LJ, Harrison CJ, Evans WE, van der Velden VHJ, Hoogerbrugge PM, van Leeuwen FN, Escherich G, Horstman M, Khankandani LM, Rizopoulos D, de Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML. Leukemia Cells with a BCR-ABL1-Like signature and/or IKZF1 deletions, but Not High CRLF2 Expression, Are Predictive of an Unfavorable Prognosis in Childhood B Cell Precursor Acute Lymphoblastic Leukemia. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
• Thakur IR, Ensor H, Jesson J, Eyre L, Hancock J, Harrison C, Morman A, Lawson S, Flow MRD Lab Network, Mol MRD Lab Network. Molecular versus flow cytometric MRD analysis - is there an explanation for discrepancies?. In: 52nd Annual Scientific Meeting of the British Society for Haematology. 2012, Glasgow, UK: Wiley-Blackwell Publishing Ltd.
• Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JPP, Beverloo HB, Zimmermann M, de Haas V, Richards SM, Vora AJ, Mitchell CD, Russell LJ, Schwab C, Harrison CJ, Moorman AV, van den Heuvel-Eibrink MM, den Boer ML, Zwaan CM. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012, 26(10), 2204-2211.
• Attarbaschi A, Morak M, Cario G, Cazzaniga G, Ensor HM, te Kronnie T, Bradtke J, Mann G, Vendramini E, Palmi C, Schwab C, Russell LJ, Schrappe M, Conter V, Mitchell CD, Strehl S, Zimmermann M, Potschger U, Harrison CJ, Stanulla M, Panzer-Grumayer R, Haas OA, Moorman AV, Assoc Italiana Ematologia Oncologi, Natl Canc Res Inst NCRI-Childrens. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. British Journal of Haematology 2012, 158(6), 772-777.
• Harrison CJ. Acute Lymphoblastic Leukemia. Clinics in Laboratory Medicine 2011, 31(4), 631-647.
• Sinclair PB, Parker H, An Q, Rand V, Ensor H, Harrison CJ, Strefford JC. Analysis of a breakpoint cluster reveals insight into the mechanism of intrachromosomal amplification in a lymphoid malignancy. Human Molecular Genetics 2011, 20(13), 2591-2602.
• Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J, Jones L, Masic D, Minto L, Morrison H, Ryan S, Robinson H, Sinclair P, Moorman A, Strefford J, Harrison CJ. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2011, 117(25), 6848-6855.
• Harrison CJ. Key pathways as therapeutic targets. Blood 2011, 118(11), 2935-2936.
• Coenen EA, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJL, Leszl A, Litvinko N, Lo Nigro L, Morimoto A, Perot C, Reinhardt D, Rubnitz JE, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood 2011, 117(26), 7102-7111.
• Coenen E, Raimondi S, Harbott J, Zimmermann M, Alonzo T, Auvrignon A, Beverloo B, Chang M, Creutzig U, Dworzak M, Forestier E, Gibson B, Hasle H, Harrison C, Heerema N, Kaspers G, Leszl A, Litvinko N, Lo Nigro L, Morimoto A, Perot C, Reinhardt D, Rubnitz J, Smith F, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Pieters R, Zwaan M, van den Heuvel-Eibrink M. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11Q23/MLL-rearranged AML patients: Results of an international study. In: Pediatric Blood & Cancer: 43rd Congress of the International Society of Paediatric Oncology (SIOP). 2011, Auckland, New Zealand: John Wiley & Sons, Inc.
• Nicholson L, Evans C, Matheson EC, Minto L, Keilty C, Schwab C, Harrison CJ, Hall AG, Redfern C, Whetton A, Irving J. Quantitative Proteomic Analysis Reveals Maturation As a Mechanism Underlying Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia and PAX5 As a Re-Sensitising Therapeutic Target. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Ryan SL, Rand V, Schwab C, Morrison H, Matheson E, Minto L, Rahman T, Keavney B, Bown N, Skinner R, Schnittger S, Santibanez-Koref M, Grossmann V, Kohlmann A, Irving J, Harrison CJ. Ras Signalling Pathway and Novel Target Genes Related to Down Syndrome Contribute to the Development of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in iAMP21 Patients. In: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
• Gibson BES, Webb DKH, Howman AJ, De Graaf SSN, Harrison CJ, Wheatley K, United Kingdom Childhood Leukaemia, Dutch Childhood Oncology Grp. Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial. British Journal of Haematology 2011, 155(3), 366-376.
• Harrison CJ. Topics in cytogenetics of acute leukaemias. In: Mutagenesis: 31st Annual Meeting of the United Kingdom Environmental Mutagen Society. 2009, University of Northumbria, Newcastle upon Tyne, UK: Oxford University Press.
• Russell L, Harrison CJ. IDENTIFICATION OF MULTIPLE NOVEL IGH@ TRANSLOCATIONS IN ADOLESCENT ACUTE LYMPHOBLASTIC LEUKAEMIA. Haematologica: the hematology journal 2008, 93(S1), 197-198.
• Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM. Treatment of infants with lymphoblastic leukaemia. British Journal of Haematology 2002, 117(2), 306-314.
• Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JKH, Stevens RF, Walker H. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. British Journal of Haematology 1999, 107(1), 69-79.
• Harrison CJ, Ross F, Radford-Weiss I, le Guyader G, Rack K, Vekemans M, Macintyre EM. Fluorescence In Situ Hybridization Analysis of Masked (8;21)(q22;q22) Translocations. Cancer Genetics & Cytogenetics 1999, 112(1), 15-20.